Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 901–1,000 of 1,000
Oljačić, S., Popovic-Nikolic, M., Filipić, B., Gagić, Ž., & Nikolic, K. M. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266337668241025061804 · Cited by 5
Mechanisms of immunotherapy resistance in small cell lung cancer
Nie, Y., Schalper, K. A., & Chiang, A. C. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.154 · Cited by 25
Lin, Y., Jin, H., She, Y., Zhang, Y., Cui, L., Xie, C., Liu, Y., Zhang, H., Guo, H., Wu, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2417529122 · Cited by 8
“Additionally, prior research has demonstrated that EZH2 epigenetically silences Th1 - type chemokines, such as CXCL9 and CXCL10, in tumor cells, thereby suppressing antitumor immunity and immunotherapy ( 22 , 23 ).”
Griffiths, E. A., Srivastava, P., Gomez, E. C., Matsuzaki, J., Odunsi, K. O., Dillon, L. W., Mukherjee, D., Hourigan, C. S., Peng, J. J., Bandyopadhyay, S., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100106 · Cited by 5
“17 Thus, the combination of immunotherapies with standard-of-care HMA therapy is an active area of clinical research in patients with MDS.”
CRISPR screens define unified hallmarks of cancer cell-autonomous immune evasion
Huber, A., Djajawi, T. M., Rivera, S., Vervoort, S. J., & Kearney, C. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116738 · Cited by 10
Chen, D., Wu, R., Liu, Z., Wei, Y., & Kuang, D. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004035 · Cited by 6
“90, 124, 160] Hence, therapeutic paradigms that limit the recruitment and M2”
Acquired resistance of cancer therapies: Mechanisms and perspectives
Wang, M., Zhai, X., Li, J., Chen, J., Gai, X., Liu, X., Liu, Y., Zhou, Q., & Chen, C. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004048 · Cited by 8
“[209] Research by Peng et al [230] found that the DNMT inhibitor 5-aza-2 ′ deoxycytidine (5-AZAdC) could reverse the production of Th1-type chemokines CXCL9 and CXCL10 in ovarian cancer, thereby relieving epigenetic silencing and promoting effector T cell trafficking to the tumor microenvironment,…”
Engineering strategies to optimise adoptive cell therapy in ovarian cancer
Guerra, C., Kalaitsidou, M., Kueberuwa, G., Hawkins, R. E., & Edmondson, R. J. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102632 · Cited by 6
Targeting the chromatin structural changes of antitumor immunity
Li, N.-N., Lun, D., Gong, N., Meng, G., Du, X., Wang, H., Bao, X., Li, X., Song, J.-W., Ke-wei, H., et al. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.11.012 · Cited by 6
“EZH2-mediated DNA methylation associated with DNMT1 and H3K27me3 may inhibit the expression of the type 1 T helper cell (TH1) chemokines CXCL9 and CXCL10, as well as the subsequent transport of effector T cells to the tumor microenvironment [64].”
BackgroundHojjatipour, T., Ajeli, M., Maali, A., & Azad, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104498 · Cited by 7
Advances in Immune Checkpoint Therapy in Hepatocellular Carcinoma
Huang, Y., & Yu, W. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0375 · Cited by 8
Gutiérrez-Sandoval, R., Gutiérrez-Castro, F., Muñoz-Godoy, N., Rivadeneira, I., Sobarzo, A., Alarcón, L., Dorado, W., Lagos, A., Montenegro, D., Muñoz, Í., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061299 · Cited by 7
“Using LC-MS/MS coupled with label-free quantification (LFQ), an average of 430–460 unique proteins per replicate [37] were identified in the fresh condition, compared to 410–445 in the concentrated group and 390–430 in cryopreserved samples [38].”
Cai, J., Wu, S., Zhang, F., & Dai, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952413 · Cited by 5
Epigenetics behind tumor immunology: a mini review
Musella, M., Manduca, N., Maccafeo, E., & Sistigu, A. (2023) · Oncogene · doi:10.1038/s41388-023-02791-7 · Cited by 5
“Similarly, depletion of the m 6 A methyltransferases METTL3 and METTL14 was shown to stabilize the STAT-1-IRF-1 axis and induce enhanced secretion of IFN-γ , CXCL9 and CXCL10 which helped to sensitize otherwise resistant mismatch-repair-pro fi cient and microsatellite instability low colorectal cancers and melanomas to…”
BackgroundPeng, X., Liu, C., Zhang, L., Chen, Y., Mao, L., Gao, S., Shi, X., & Zuo, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1365683 · Cited by 5
The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions
Horton, B. L., & Spranger, S. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170073 · Cited by 5
Epigenetics in Melanoma Development and Drug Resistance
Hammerlindl, H., & Schaider, H. (2018) · InTech eBooks · doi:10.5772/intechopen.70983 · Cited by 5
“For example, H3K4me3 dependent PD-L1 expression has been observed in pancreatic cancer [102] or H3K27me3 and DNA methylation-mediated silencing of Th1-type chemokines CXCL9 and CXCL10 in ovarian cancer cells [103], suggesting an important role for histone modifications in the regulation of immunomodulatory factors acr…”
BackgroundInsight into the dichotomous regulation of STING activation in immunotherapy
Hu, Z., Yang, Y. K., Fang, L., Zhou, J., & Zhang, H. (2021) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2021.1890118 · Cited by 5
Novel therapies targeting cutaneous T cell lymphomas and their microenvironment
Reneau, J. C., & Wilcox, R. A. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.02.002 · Cited by 5
Vlachostergios, P. J. (2021) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2021.100035 · Cited by 5
PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer
Sedley, S., Nag, J. K., Rudina, T., & Bar‐Shavit, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158758 · Cited by 6
“It has been shown to be negatively correlated with CD8+ cytotoxic T cells in ovarian cancer [55].”
BackgroundGenetics and anatomy sculpt immune-cell partners of ovarian cancer
Laniti, D. D., & Coukos, G. (2022) · Nature · doi:10.1038/d41586-022-04169-3 · Cited by 5
Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities
Fearon, D. T. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030783 · Cited by 6
“There is evidence in support of the first explanation with the finding of epigenetic silencing of CXCL9 and CXCL10 as a means by which a preclinical tumor model circumvents immune control (Peng et al. 2015).”
BackgroundPerspectives on Epigenetics and Cancer Immunotherapy: A Preface to Special Issue
Álvarez‐Errico, D. (2021) · Cancers · doi:10.3390/cancers13061452 · Cited by 5
“For instance, the epigenetic repression of immune signature genes that promote effective anti-tumoral responses, such as IFN-γ-mediated Th1 type responses, promotes cancer progression and conditions beneficial clinical responses to immunotherapy [7].”
BackgroundNew generation of clinical epigenetics analysis and diagnosis for precision medicine
Song, P., & Li, B. (2025) · Diagnostics · doi:10.3390/diagnostics15121539 · Cited by 4
Green, H. L. H., Sum, H., Sinha, P., Visnagri, A., Lee, S. H., Baffour-Kyei, A., Lee, H., Santos, F. G. D. A., Theofilatos, K., & Brewer, A. C. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110520 · Cited by 4
“Crucially, previous reports have demonstrated the importance of epigenetic marks within this region in the regulation of CXCL9, CXCL10, and CXCL11 expression, suggesting that it acts as an enhancer (50–52).”
Nguyen, T. T. T., Dang, X. T. T., Phung, C. D., Tran, L. T. N., Do, N. T. P., Yeo, E. Y. M., Tran, N. M., Yeo, B. Z. J., Lixuan, C. P., Nguyen, N. T. H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114239 · Cited by 4
Božič, T., Šantek, I., Pisljar, Z., Kranjc, S., Serša, G., Markelc, B., & Čemažar, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118887 · Cited by 4
Huang, S.-W., Liang, Y., Tao, Y., Li, W., Zhou, G., Mao, Y., Guo, R., Chen, L., Xu, S., Liu, X., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02111 · Cited by 4
Self-citationLi, H., Wang, Z., Liang, H., Liu, X., Liu, H., Zhuang, Z., & Hou, J. (2024) · Biomolecules · doi:10.3390/biom14020232 · Cited by 4
“Additionally, we found that the migration of immune cells into tumors is dependent on chemokines and their receptors [33,34].”
BackgroundGutiérrez-Sandoval, R., Gutiérrez-Castro, F., Muñoz-Godoy, N., Rivadeneira, I., Sobarzo, A., Iturra, J., Krakowiak, F., Alarcón, L., Dorado, W., Lagos, A., et al. (2025) · Cancers · doi:10.3390/cancers17101658 · Cited by 6
“2) revealed 284 significantly upregulated proteins (log FC ≥ 1.5; FDR ≤ 0.01) included the • SDCBP (2.1× increase): a sca ff old protein for vesicular stability and ICAM-related signaling [37,38].”
InfluentialEpner, E. M., Saroya, B. S., Hasanali, Z. S., & Loughran, T. P. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2015.12.011 · Cited by 4
Cui, B., Cao, X., Zou, W., Wan, Y., Wang, N., Wang, Y., Li, P., Hua, F., Liu, Y., Zhang, X., et al. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.06.007 · Cited by 4
Self-citationClinical significance of promoter hypermethylation of genes in ovarian cancer
Zhu, X., & Lang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23758 · Cited by 5
“com/oncotarget improved the therapeutic efficacy of adoptive T-cell transfusion and programmed death ligand 1 (PD-L1) inhibitor in mice bearing OC [27].”
BackgroundResultCancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm
Lee, D. Y. (2020) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-20-18 · Cited by 4
“Peng et al([47]) found that selective inhibitors of DNMT1 and enhancer of zeste homolog 2 (EZH2)—proteins that catalyze their respective epigenetic marks—reversed transcriptional repression and improved response to programmed death-ligand 1 (PD-L1) blockade as well as to adoptive T-cell therapy.”
BackgroundZhang, L., Jin, J., Qin, W., Jiang, J. T., Bao, W., & Sun, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032394 · Cited by 4
“While the high selectivity of GSK126 has already been well confirmed and extensive studies in the tumor field suggest that the effect of GSK126 in treating tumors is through its inhibition of EZH2 [25,29,49,59], additional EZH2 knockdown experiment may provide further evidence about the function of EZH2.”
BackgroundHsu, C., Mohammed, A. N., Hjazi, A. M., Uthirapathy, S., RenukaJyothi, S., Singh, A., Thyagarajan, Ray, S., & Hulail, H. M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03883-9 · Cited by 4
“In an animal model of human ovarian cancer, Th1 chemokines CXCL9 and CXCL10 were elevated after EZH2 suppression, which boosted effector T cell recruitment and improved the beneficial outcomes of PD-L1 ICB therapy and adoptive T cell infusion in tumor-bearing mice (Peng et al. 2015).”
Chou, M.-Y., & Yang, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102353 · Cited by 6
“…methyltransferases (e.g., EZH2), have the potential to restore Th1 cytokine expression (e.g., CXCL9/10) and facilitate improved T-cell trafficking [160] Given that ICIs primarily exert their therapeutic effects within the TIME, a significant focus of current research lies in reversing the escape…”
Targeting the Tumor-Associated Macrophages for ‘Normalizing’ Cancer
Kzhyshkowska, J. G., Grigoryeva, E., & Larionova, I. (2020) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-32857-3_11 · Cited by 4
Epi-Regulation of Cell Death in Cancer
Beato, A., Torre, L. D., Capone, V., Carannante, D., Favale, G., Verrilli, G., Altucci, L., & Carafa, V. (2023) · Biochemistry · doi:10.5772/intechopen.108919 · Cited by 4
Luo, J., Shi, X., Liu, Y., Wang, J., Wang, H., Yang, X., Sun, Q., Hui, Z., Wei, F., Ren, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1302761 · Cited by 5
“The chemokines C-X-C motif chemokine ligands 9 and 10 play important roles in T cell in fi ltration (13 – 16); however, the exact mechanisms of lymphocyte entry into the TME remain poorly de fi ned.”
BackgroundReducing silence to improve therapy
Kugelberg, E. (2015) · Nature reviews. Immunology · doi:10.1038/nri3941 · Cited by 4
An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies
Dai, M., Yip, Y. Y., Hellström, I., & Hellström, K. E. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000135 · Cited by 4
Exploring the role of EZH2 modulation in shaping the tumor microenvironment
Fischetti, I., Michele, D. L., & Jachetti, E. (2024) · Epigenomics · doi:10.1080/17501911.2024.2410693 · Cited by 6
Steroids and One-Carbon Metabolism: Clinical Implications in Endocrine Disorders
Scheyer, N., Guéant‐Rodriguez, R., Agopiantz, M., & Leininger‐Muller, B. (2025) · Neuroendocrinology · doi:10.1159/000547151 · Cited by 4
Photo-triggered engineered microbes achieving dual epigenetic immunomodulation for gastric cancer
Lou, C., Li, Y., Zhan, R., Fang, Y., Zhang, A.-Q., Liu, Y., Li, S., Liu, X., Fan, R., Yuan, M., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123608 · Cited by 3
LD-110, a potent LSD1 PROTAC degrader, suppresses tumor growth by inducing ER stress and apoptosis
Zhai, D., Zhuo, J., Yin, Y., Li, L., Liang, M., Zhou, X., Liu, L., Chen, L., Xiong, X., Yang, Y. P., et al. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.10.024 · Cited by 4
Self-citationGyau, B. B., & Man, T.-K. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010319 · Cited by 5
Calabrò, L., Caruso, F. P., Covre, A., Noviello, T., Lofiego, M. F., Tufano, R., Ferraro, L., Grisolia, P., Falco, A. D., Lagano, V., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02580-4 · Cited by 3
“…the gene expression signatures of the sarco-matoid, epithelioid, biphasic-E and biphasic-S 11 to classify each sample based on the signature with the highest average gene expression score, resulting in 26 tumors classified as sarcomatoid, 19 as biphasic-S, 16 as biphasic-E and 15 as epithelioid.”
Histone modifications across cancers: mechanisms, therapy and clinical translation
Lu, P., Chan, Y.-T., Kwok, C.-F., Li, Q., Jiang, Z., Xu, L., Feng, Z., Yuan, H., Zou, J., Xun, Y., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02707-5 · Cited by 5
“The repressive histone modification H3K27me3, catalyzed by EZH2 in its role as the catalytic unit of PRC2, directly inhibits the transcription of T-helper 1 (Th1)-type chemokines CXCL9 and CXCL10, which play a key role in attracting effector CD8 + T cells into tumors [70].”
The Emerging Epigenetic Landscape in Melanoma
Rollins, R. A., Kim, K. H., & Tsao, C. (2016) · InTech eBooks · doi:10.5772/64733 · Cited by 3
“In addition, EZH2 promotes immune evasion and suppression by directly repressing the expression of chemokines and cell surface antigens [75, 160, 161].”
BackgroundLing, Y., Wang, Y., Cao, C., Feng, L., Zhang, B., & Li, S. (2022) · Aging · doi:10.18632/aging.204379 · Cited by 6
Mylod, E., O’Connell, F., Donlon, N. E., Davern, M., Marion, C., Butler, C., Reynolds, J. V., Lysaght, J., & Conroy, M. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54390-5 · Cited by 5
Wang, Y., Chen, Y., & Zhao, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01048-3 · Cited by 3
“Selective inhibitors of EZH2 methyltransferase activity, like ESK126, have demonstrated the ability to synergistically enhance the therapeutic efficacy of T cell therapy while increasing the infiltration of CXCL9 and CXCL10 chemokines, as well as CD8 + T cells [69].”
BackgroundUpadhyay, S., Kumar, S. B., Singh, V. K., Tiwari, R., Kumar, A., Sundar, S., & Kumar, R. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.36 · Cited by 5
Zhou, L., Cheng, W., Luo, Q., Huang, C., & Li, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115012 · Cited by 3
Epigenetic Regulation of Immune Responses in Endocrine-Related Cancers and Its Role in Immunotherapy
Akyuz, E. M., Gultekin, M., Ramage, J. M., Spendlove, I., Jackson, A. M., Adhikaree, J., & Malecka, A. A. (2025) · Cancers · doi:10.3390/cancers17203342 · Cited by 5
“Treatment of mice with EZH2 inhibitor, 3-Deazaneplanocin A (DZNep) or DAC reversed this repression of CXCL9 and CXCL10 and improved responses to CD8 + T cell therapy in an ovarian cancer model [109].”
Stem Cells in Breast Development and Cancer
Azizi, E., Granger, J. I., Harouaka, R. A., Luther, T. K., & Wicha, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00023-4 · Cited by 3
Overcoming Endocrine Resistance in Breast Cancer
Ferrari, P., & Nicolini, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00029-6 · Cited by 4
Teng, Y., Wang, B., Shang, D., & Yang, N. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.764869 · Cited by 3
The cancer epigenome: Non‐cell autonomous player in tumor immunity
Kato, S., Maeda, Y., Sugiyama, D., Watanabe, K., Nishikawa, H., & Hinohara, K. (2022) · Cancer Science · doi:10.1111/cas.15681 · Cited by 5
Sharif, P. M., Khoshbin, A. P., Nasrollahzadeh, E., Keshavarz‐Fathi, M., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00003-7 · Cited by 8
Lukes, A. S., Dial, S., Dart, C., & Peipert, J. F. (2023) · EMJ Reproductive Health · doi:10.33590/emjreprohealth/10309507 · Cited by 3
Zaalberg, A., Pottendorfer, E., Zwart, W. T., & Bergman, A. M. (2024) · Cancers · doi:10.3390/cancers16020294 · Cited by 6
Squamous Cell Carcinoma in Never Smokers: An Insight into SMARCB1 Loss
Patel, A. J., Hemead, H. M., Jesani, H., Billè, A., Tanière, P., & Middleton, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158165 · Cited by 3
“EZH2 inhibition has been shown to increase the infiltration of CD8+ T cells in ovarian cancer models [43], and comparisons of tumor biopsy samples obtained prior to and during Tazemetostat revealed a substantial increase in intra-tumoral and stromal infiltrates of CD8+ cytotoxic and FOXP3+…”
BackgroundSun, Y., Ding, S., Shen, F., Yang, X., Sun, W., & Wan, J. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112584 · Cited by 3
Self-citationIntegrated analyses of prognostic and immunotherapeutic significance of EZH2 in uveal melanoma
Li, J., Zhang, Y., Qiu, Y., & Qu, Y. (2025) · Methods · doi:10.1016/j.ymeth.2025.01.004 · Cited by 3
Imaging in Advanced Non–Small Cell Lung Cancer
Dimou, A., Sherman, C. A., & Wrangle, J. M. (2016) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000219 · Cited by 3
Immune Checkpoint Inhibitors Therapy in Prostate Cancer: Lessons Learnt
Chandok, M. R. (2020) · Annals of Immunology & Immunotherapy · doi:10.23880/aii-16000119 · Cited by 3
Mechanisms of resistance to immune checkpoint inhibitors
Liu, X., & Guan, Q. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i17.857 · Cited by 3
Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistancePreprint
Maitituoheti, M., Shi, A., Tang, M., Ho, L., Terranova, C. J., Galani, K., Keung, E. Z.-Y., Creasy, C. A., Wu, M., Chen, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.31.506051 · Cited by 3
Li, W., Liu, H., Li, W., Zhang, Q., Zhang, Q., & Hu, D. (2023) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00368-9 · Cited by 2
“An accelerated role of EZH2 in the construction of an immunosuppressive microenvironment has been demonstrated in breast cancer (Peng et al. 2015).”
Liu, Q., Li, M., Xiong, Y., Shen, Y., Ma, T., Zhang, T., Yang, X. R., Zhang, Y., & Bai, J. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101133 · Cited by 2
Wang, K., Shi, J., Tong, X., Qu, N., Kong, X., Ni, S., Xing, J., Li, X., & Zheng, M. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae017 · Cited by 2
“Increased expression of CXCL9, CXCL10 and CXCL11 can enhance T cell infiltration and promote the therapeutic effect of ICIs [46–48].”
BackgroundHuang, R., Han, B. R., Zhang, Y., Yang, J., Wang, K., Liu, X., & Wang, Z. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18208 · Cited by 2
“As shown in Figure 3C , HIS sub - type was associated with high expression of T helper 1 (Th1)/cytotoxic T lymphocyte (CTL)- related genes (Especially CXCL9 , CXCL10 , GZMA , and GZMB ) 37 ( Figure 3D).”
ResultH3K27me3-mediated regulation of PD-L1 expression in triple-negative breast cancer (TNBC)
Harada, J., Kawashima, K., Matsubara, Y., Oshi, M., Sasamoto, M., Yamada, A., Suganuma, N., & Fujii, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155872 · Cited by 2
Li, J., Luo, W., Nie, D., Lin, Z., & Zhou, C. (2025) · Epigenetics · doi:10.1080/15592294.2025.2527145 · Cited by 2
“Recent research suggests that aberrant DNA methylation patterns in cancer cells contribute to immune evasion and tumorigenesis [17,18].”
STK25 Loss Augments Anti‐PD‐1 Therapy Efficacy by Regulating PD‐L1 Stability in Colorectal Cancer
Qiao, X., Xing, P., Hao, H., Chen, J., Song, L., Hou, Y., Yang, X., Weng, K., Chen, J., Gao, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202503891 · Cited by 5
Zhang, D., Tang, Y., Sun, W., Guan, Y., Cheng, Y., Zhu, Y., Zhao, X., Yang, X., & Zhu, H. (2025) · iScience · doi:10.1016/j.isci.2025.113463 · Cited by 3
“8,9 The presence of CCL20 in human tumor microen-vironments suggests that this chemokine profile may facilitate T cell trafficking into tumors.”
Endo, Y., Sugino, R. P., Takenobu, H., Mukae, K., Okada, R., Shinno, Y., Haruta, M., Satoh, S., Akter, J., Hattori, N., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14882-7 · Cited by 2
Wei, Q., Zhao, K., Wu, Y., Wu, W., & Hao, N. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70531 · Cited by 2
Chi, X., Dong, Y., Zhu, L., Su, D., & Wu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1693401 · Cited by 3
“Recently, several pre-clinical and early-phase studies have combined histone deacetylase inhibitors (HDACi) (e.g., vorinostat, entinostat) or DNA methyltransferase inhibitors (DNMTi) (e.g., azacitidine, decitabine) with ICIs in NSCLC (167 – 171).”
Lang, S. M., Tallapragada, S., Chan, J., & Dorigo, O. (2025) · Cancers · doi:10.3390/cancers17243925 · Cited by 2
“In fact, higher CXCL10 levels have been correlated with greater T-cell infiltration in ovarian tumors, while its silencing results in immune exclusion and poor outcomes [24,25].”
Yan, Q., Qingqing, Z., Yu, S., & Zhang, W. (2025) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2025.2598380 · Cited by 3
“The KMT6A enzyme may regulate the production of the chemokines CXCl9 and CXCl10, both of which are responsible for T cell recruitment and infiltration. on the other hand, the KDM6 factor causes autocrine regulation of chemokines [44].”
Ye, P., Wen, Y., Liu, R., Gao, W., Li, Q., Ma, B., & Dong, C. (2026) · npj Breast Cancer · doi:10.1038/s41523-026-00893-5 · Cited by 3
“CXCL9,asoneoftheThelper1(Th1)-typechemokines,couldrecruitTand NKcells 8,9,23 .”
Self-citationTargeting epigenetic regulators to boost T cell immunotherapy against cancer
Xiao, T., & Zhang, Y. E. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01533-y · Cited by 2
Bioinformatic analysis and cellular functional assays uncover the role of NXPH4 in breast cancer
Yang, D. D., Xue, Z. K., Jia, S. Q., Liu, C. H., Yang, R., Chen, C. L., Huang, Y. Z., Zhao, X. C., Huang, G. L., & Hou, J. X. (2026) · Discover Oncology · doi:10.1007/s12672-026-04519-x · Cited by 2
Targeting cellular source-specific CXCL9 signaling for immunotherapy in oral squamous cell carcinoma
Qiu, M., Wang, L., Tang, H., & Jiang, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1768606 · Cited by 3
Zhou, Y., Yu, J., Sui, Q., Liao, L., Lv, R.-X., Liu, Y., He, S., Li, Y.-Q., Xu, Z.-H., Jia, Z., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218683 · Cited by 3
Cojocaru, E., Scaranti, M., & Minchom, A. R. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_24_18 · Cited by 2
“[2] The major histocompatibility complex (MHC) consists of cell surface proteins that bind antigens and display for recognition by T-cells.”
BackgroundInfluentialUnderstanding the Crosstalk Between Epigenetics and Immunometabolism to Combat Cancer
Seth, A., & Kar, S. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-07634-3_18 · Cited by 3
Tan, T. G., Zybina, Y., McKenna, C., Olow, A., Rukmini, S. J., Wong, M. T., Sadekova, S., Chackerian, A. A., & Bauché, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016307 · Cited by 2
Immunogenic Cell Death in Cancer
Humeau, J., Naour, J. L., Kroemer, G., & Pol, J. G. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_121 · Cited by 2
Zhang, X.-M., Zhang, Y., Zhang, Q., Lu, M., Chen, Y., Zhang, X.-Y., & Zhang, P. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18063 · Cited by 1
“85 This finding highlights the potential immunomodulatory effects of targeting EZH2 in cancer therapy.”
BackgroundTorasawa, M., Yoshida, T., Shiraishi, K., Yagishita, S., Ono, H., Uehara, Y., Miyakoshi, J., Tateishi, A., Igawa, Y. S., Higashiyama, R. I., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108494 · Cited by 5
Functional Genome Profiling to Understand Cancer Immune Responsiveness
Wang, E., Bedognetti, D., & Marincola, F. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_11 · Cited by 2
Sammons, S. L., McNamara, M. A., Salama, A. K. S., & Crawford, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-70253-7_12 · Cited by 2
Novel targeted agents for follicular lymphoma
Batlevi, C. L., & Morschhauser, F. (2021) · Annals of Lymphoma · doi:10.21037/aol-20-45 · Cited by 2
Tseng, D., Schultz, L. M., Pardoll, D. M., & Mackall, C. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00006-2 · Cited by 3
Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma
LeBlanc, F., Hasanali, Z. S., Stuart, A., Shimko, S., Sharma, K., Leshchenko, V. V., Parekh, S. S., Fu, H., Zhang, Y., Martin, M. M., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28258 · Cited by 2
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.